TY - JOUR T1 - Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2016.PA4903 VL - 48 IS - suppl 60 SP - PA4903 AU - Hans Bisgaard AU - Dan Lythgoe AU - Carin Jorup Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/suppl_60/PA4903.abstract N2 - BACKGROUND: Adolescent patients with asthma are not thought to differ from adults in terms of clinical treatment efficacy.AIM AND OBJECTIVE: This analysis of 6 double-blind studies (6–12 months) assessed the efficacy/safety of budesonide/formoterol (BUD/FORM) maintenance and reliever therapy (MART) in adolescent patients (12–17 yrs) with asthma.METHODS: BUD/FORM MART was compared with active comparators (Figure) for time to first severe exacerbation (primary endpoint, except STEAM) and other efficacy parameters. Severe exacerbations were defined as hospitalisation/emergency treatment due to asthma worsening and need for oral steroids for asthma. Safety was assessed by adverse event (AE) type/incidence.RESULTS: Overall, 1845 adolescent patients were included in the individual study efficacy population. BUD/FORM MART was similar to, or more effective than, comparators across all studies for time to first severe exacerbation, with comparable outcomes for adolescents and adults (Figure). Adult/adolescent patients using BUD/FORM MART received a lower mean daily dose of inhaled corticosteroid versus comparators, when study design allowed. AE type/incidence were similar for adults and adolescents on BUD/FORM MART versus comparators across studies.CONCLUSIONS: The efficacy and safety of BUD/FORM MART in adolescent asthma patients is similar to that in adults.FUNDING: AstraZeneca ER -